TrialBlood2012

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

H Jean Khoury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.